

# 정신분열증 치료의 Augmentation Strategies

정 영 기\*†

## Augmentation Strategies for the Treatment of Schizophrenia

Young Ki Chung, M.D.\*†

### ABSTRACT

Antipsychotic drugs (APDs) have been effective to alleviate psychotic symptoms of schizophrenia. However, some schizophrenic patients do not respond to APDs. In addition to psychotic symptoms of schizophrenia, negative symptoms, excitement, violence, agitation, depression, and disorganization are frequently noted in patients with schizophrenia. Though APDs are the first line drugs for these symptoms, other drugs than APDs to augment the effects of APDs are efficacious for the treatment of these symptoms. Such augmenting drugs include benzodiazepines, anticonvulsants, antidepressants, lithium, and electroconvulsive therapy. These augmentation strategies can boost the effects of APDs or decrease the requirements of APDs, and consequently decrease the chance of the occurrence of side effects of APDs. Augmenting strategies are reviewed for each class of drugs or treatment modality.

**KEY WORDS :** Schizophrenia · Antipsychotic drugs · Augmentation.

### 서 론

정신분열증 환자에게는 항정신병약물(antipsychotic drugs, APDs)이 정신병적 증상을 완화하는데 효과적이다. 그러나 일부 정신병 환자는 APDs에 반응하지 않는다. 정신병 증상에 추가하여, 부정적 증상, 흥분, 폭력, 불안, 우울, 그리고 조직화 장애는 정신병 환자에서 흔히 관찰된다. APDs는 이러한 증상들을 치료하기 위한 1차 약물이다. 그러나 APDs 이외의 다른 약물들이 APDs의 효과를 증진시키거나 APDs의 요구량을 줄여주어, 결과적으로 APDs의 부작용 발생 가능성을 감소시킬 수 있다. 증진 전략은 각 약물 종류 및 치료 방법에 대해 검토된다.

정신분열증 환자에게는 항정신병약물(antipsychotic drugs, APDs)이 정신병적 증상을 완화하는데 효과적이다. 그러나 일부 정신병 환자는 APDs에 반응하지 않는다. 정신병 증상에 추가하여, 부정적 증상, 흥분, 폭력, 불안, 우울, 그리고 조직화 장애는 정신병 환자에서 흔히 관찰된다. APDs는 이러한 증상들을 치료하기 위한 1차 약물이다. 그러나 APDs 이외의 다른 약물들이 APDs의 효과를 증진시키거나 APDs의 요구량을 줄여주어, 결과적으로 APDs의 부작용 발생 가능성을 감소시킬 수 있다. 증진 전략은 각 약물 종류 및 치료 방법에 대해 검토된다.

정신분열증 환자에게는 항정신병약물(antipsychotic drugs, APDs)이 정신병적 증상을 완화하는데 효과적이다. 그러나 일부 정신병 환자는 APDs에 반응하지 않는다. 정신병 증상에 추가하여, 부정적 증상, 흥분, 폭력, 불안, 우울, 그리고 조직화 장애는 정신병 환자에서 흔히 관찰된다. APDs는 이러한 증상들을 치료하기 위한 1차 약물이다. 그러나 APDs 이외의 다른 약물들이 APDs의 효과를 증진시키거나 APDs의 요구량을 줄여주어, 결과적으로 APDs의 부작용 발생 가능성을 감소시킬 수 있다. 증진 전략은 각 약물 종류 및 치료 방법에 대해 검토된다.

정신분열증 환자에게는 항정신병약물(antipsychotic drugs, APDs)이 정신병적 증상을 완화하는데 효과적이다. 그러나 일부 정신병 환자는 APDs에 반응하지 않는다. 정신병 증상에 추가하여, 부정적 증상, 흥분, 폭력, 불안, 우울, 그리고 조직화 장애는 정신병 환자에서 흔히 관찰된다. APDs는 이러한 증상들을 치료하기 위한 1차 약물이다. 그러나 APDs 이외의 다른 약물들이 APDs의 효과를 증진시키거나 APDs의 요구량을 줄여주어, 결과적으로 APDs의 부작용 발생 가능성을 감소시킬 수 있다. 증진 전략은 각 약물 종류 및 치료 방법에 대해 검토된다.

정신분열증 환자에게는 항정신병약물(antipsychotic drugs, APDs)이 정신병적 증상을 완화하는데 효과적이다. 그러나 일부 정신병 환자는 APDs에 반응하지 않는다. 정신병 증상에 추가하여, 부정적 증상, 흥분, 폭력, 불안, 우울, 그리고 조직화 장애는 정신병 환자에서 흔히 관찰된다. APDs는 이러한 증상들을 치료하기 위한 1차 약물이다. 그러나 APDs 이외의 다른 약물들이 APDs의 효과를 증진시키거나 APDs의 요구량을 줄여주어, 결과적으로 APDs의 부작용 발생 가능성을 감소시킬 수 있다. 증진 전략은 각 약물 종류 및 치료 방법에 대해 검토된다.

Department of Psychiatry, School of Medicine, Ajou University, Suwon, Korea

\* : 0331-442-749, 5 (0331) 219-5182, (0331) 219-5179

가 augmentation (psychotic symptoms) augmentation Benzodiazepine 가 (placebo) 가 benzodiazepine augmentation strategies intermediate high potency benzodiazepine augmentation benzodiazepine triazolobenzodiazepine (Lingjaerde 1985). 가 augmentation (Nishkawa 1982) (Arana 1986) benzodiazepine (Roberts Vass 1986) benzodiazepine (rapid tranquilization) benzodiazepine (Barbee 1992 ; Battaglia 1997). 가 alprazolam (Kahn 1988). preclinical study alprazolam benzodiazepine (Wolkowitz 1992). benzodiazepine (Wolkowitz 1988). benzodiazepine augmentation 가 benzodiazepine augmentation (Wolkowitz Pickar 1992). Benzodiazepine homovanillic acid (HVA) (Wolkowitz 1988), (Wolkowitz 1988) . Fluphenazine alprazolam augmentation HVA 가 alprazolam HVA 가 HVA alprazolam benzodiazepine augmentation dopamine HVA benzodiazepine augmentation (motor retardation) (Kellner 1975 ; Wolkowitz 1988). benzodiazepine (Adan Siris 1989). benzodiazepine (acute effect) (Wolkowitz Pickar 1991). benzodiazepine augmentation (Wolkowitz 1986), 가 (Pato 1988). benzodiazepine behavioral disinhibition (anticatatonic effect)(Menza Harris 1989), (Pato 1988), (Yassa 1989 ; Do- yon 1989) 가 benzodiazepine (Salzman 1988).

**항경련제(Anticonvulsants)**

Carbamazepine : benzodiazepine 가 carbamazepine augmentation (Wo-

augmentation 가 (Christison 1991).  
 (Christison 1991). lithium  
 carbamazepine , lithium BPRS  
 (Terao 1995). Carman  
 carbamazepine 가 (Klein 1984 ; We - (1981) 가  
 tterling 1987). lithium  
 (Schulz 1990). Kahn (1990) haloperidol . Atre - Vaidya Taylor(1989)  
 carbamazepine haloperidol , 가  
 가 haloperidol 50% 가 lithium .  
 가 carbamazepine haloperidol  
 monitor 가 (Wilson 1993).  
 가 haloperidol carbamazepine lithium 가  
 carbamazepine (Collins 1991).

### 항우울제(Antidepressants)

가 (Dose 1987).  
 가  
 Okuma (1989) carbamazepine 가  
 pine , BPRS ,  
 , carbamazepine  
 carbamazepine  
 (Okuma 1989). Simhandl Me -  
 szaros(1992)  
 가 supersensitive ps -  
 ychosis carbamazepine 가  
 (Chouinard Sultan 1990).  
 Carbamazepine augmentation 가  
 (Moller  
 von Zerssen 1986).  
 augmentation strategies  
 가 Plasky(1991) Siris  
 가  
 1995). . Siris (1994)  
 Valporate : valporate (postpsychotic depression)  
 augmentation  
 Lithium  
 augmentation  
 . Lerner (1988) , (serotonin reu -  
 lithium . lithium ptake inhibitor)(Silver Nassar 1992), (Siris  
 1991)가  
 lithium augmentation 가 . Goff (1990) Spina (1994) fluoxetine  
 (monoamine oxidase : MAO)  
 tranlycypromine (Bucci 1987), MAOB se -  
 legiline(Bodkin 1996)

가 . Spina (Fisch 1987). Tandon (1988)  
 fluoxetine  
 . Goff (1995) fluoxetine trihexyphenidyl  
 haloperidol . Clo - Oyewumi (1994) H2 Famotidine  
 zapine -  
 가 - fluvoxamine . opiate  
 가 (Silver 1996).  
 가 . nalmefene  
 augmentation (Rapaport 1993).  
 augmentation strategy ECT  
 가 (Siri 1978).

### 전기충격요법 (Electroconvulsive therapy : ECT)

ECT augmentation 가  
 가  
 ECT (Weiner 1979)  
 ECT ECT  
 (Rahman 1968). Weiner Coffey(1986)  
 가  
 ECT augmentation  
 Christison (1991) Meltzer(1992)  
 가  
 . Christison (1991)  
 (catatonia), 가  
 ECT가

### 기 타 제 제

augmentation 가 au -  
 augmentation  
 . Sheppard(1979) Eccleston (1985) pr -  
 propranolol 가  
 dopamine agonists가 . L - dopa(Al -  
 pert 1978) d - amphetamine(Cesarec Nyman 1985)  
 dopamine agonists  
 가  
 (activation) 가

### 참고문헌

- Adan F, Siris SG(1989)** : *Trials of adjunctive alprazolam in negative symptom patients. Can J Psychiatry* 34 : 326-328
- Alpert M, Friedhoff AJ, Marcos LR et al(1978)** : *Paradoxical reaction to L-dopa in schizophrenic patients. Am J Psychiatry* 135 : 1327-1332
- Arana GW, Ornstein ML, Kanter F, et al(1986)** : *The use of benzodiazepines for psychotic disorders : a literature review and preliminary clinical findings. Psychopharmacol Bull* 22 : 77-87
- Atre-Vaidya N, Taylor MA(1989)** : *Effectiveness of lithium in schizophrenia : Do we really have an answer? J Clin Psychiatry* 50 : 170-173
- Barbee JG, Mancuso DM, Freed CR, Todorov AA(1992)** : *Alprazolam as a neuroleptic adjunct in the emergency treatment of schizophrenia. Am J Psychiatry* 149 : 506-510
- Battaglia J, Moss S, Rush J, Kang J, Mendoza R, Leedom L, Dubin W, McGlynn C, Goodman L(1997)** : *Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, doubleblind, emergency department study. Am J Emerg Med* 15 : 335-340
- Bodkin JA, Cohen BM, Salomon MS, Cannon SE, Zornberg GL, Cole JO(1996)** : *Treatment of negative symptoms in schizophrenia and schizoaffective disorder by selegiline augmentation of antipsychotic medication. A pilot study examining the role of dopamine. J Nerv Ment Dis* 184 : 295-301
- Bucci L(1987)** : *The negative symptoms of schizophrenia and the monoamine oxidase inhibitors. Psychopharmacology* 91 : 104-108
- Caramn JS, Bigelow LB, Wyatt RJ(1981)** : *Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients. J Clin Psychiatry* 42 : 124-128
- Cesarec Z, Nyman AK(1985)** : *Differential effects to amphetamine in schizophrenia. Acta Psychiatr Scand* 71 : 523-528

- Chouinard G, Sultan S(1990)** : Treatment of supersensitive psychosis with antiepileptic drugs : Report of a series of 43 cases. *Psychopharmacol Bull* 26 : 337-341
- Christison GW, Kirch DG, Wyatt RJ(1991)** : When symptoms persist : Choosing alternative somatic treatment for schizophrenia. *Schizophr Bull* 17 : 217-245
- Collins PJ, Larkin EP, Schubsachs AP(1991)** : Lithium carbonate in chronic schizophrenia-a brief trial of lithium carbonate added to neuroleptics for treatment of resistant schizophrenic patients. *Acta Psychiatr Scand* 84 : 150-154
- Dose M, Apelt S, Emrich HM(1987)** : Carbamazepine as an adjunct antipsychotic therapy. *Psychiatry Res* 22 : 303-310
- Douyon R, Angrist B, Peselow E, Cooper T, Rotrosen J(1989)** : Neuroleptic augmentation with alprazolam : Clinical effects and pharmacokinetic correlates. *Am J Psychiatry* 146 : 231-234
- Fisch RJ(1987)** : Trihexyphenidyl abuse : Therapeutic implications for negative symptoms of schizophrenia. *Acta Psychiatr Scand* 75 : 91-94
- Goff DC, Brotman AW, Waites M, McCormicks S(1990)** : Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients. *Am J Psychiatry* 147 : 492-494
- Goff DC, Midha KK, Sarid-Segal O, Hubbard JW, Amico E(1995)** : A placebo controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia. *Psychopharmacology* 117 : 417-423
- Johns CA, Thompson JW(1995)** : Adjunctive treatments in schizophrenia : pharmacotherapy and electroconvulsive therapy. *Schizophr Bull* 21 : 607-619
- Kahn JP, Puertollano MA, Schane MD, Klein DF(1986)** : Adjunctive alprazolam for schizophrenia with panic anxiety : Clinical observation and pathogenetic implications. *Am J Psychiatry* 145 : 742-744
- Kellner R, Wilson RM, Muldrew MD, Pathak D(1975)** : Anxiety in schizophrenia. The responses to chlorthalidoxepoxide in an intensive design study. *Arch Gen Psychiatry* 32 : 1246-1254
- Klein E, Bental E, Lerer B, Belmaker RH(1984)** : Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study. *Arch Gen Psychiatry* 41 : 165-170
- Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavichia S, Little P, Schmidt R, Kimes I(1989)** : Antidepressants in depressed schizophrenic inpatients. A controlled trial. *Arch Gen Psychiatry* 46 : 922-928
- Lerner Y, Mintzer Y, Schestatzky M(1988)** : Lithium combined with haloperidol in schizophrenic patients. *Br J Psychiatry* 153 : 359-362
- Lingjaerde O(1991)** : Benzodiazepines in the treatment of schizophrenia : An updated survey. *Acta Psychiatr Scand* 84 : 453-459
- Lingjaerde O(1985)** : Antipsychotic effect of the benzodiazepine. In : *Antipsychotics* ed. by Burrows GD, Norman TR, Davies B. Amsterdam, Elsevier
- Meltzer HY(1992)** : Treatment of the neuroleptic nonresponsive schizophrenic patient. *Schizophr Bull* 18 : 515-542
- Menza MA, Harris D(1989)** : benzodiazepine and catatonia : An overview. *Biol Psychiatry* 26 : 842-846
- Moller HJ, von Zerssen D(1986)** : Depression in schizophrenia. In : *Burrow GD, Norman TR, Rubinstein G (eds) : Handbook of Studies of Schizophrenia, Part I, PP 183-191.* Elsevier, Amsterdam
- Nishikawa T, Tsuda A, Tanaka M, et al(1982)** : Prophylactic effect of neuroleptics in symptom-free schizophrenics. *Psychopharmacology* 77 : 701-704
- Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K(1989)** : A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. *Acta Psychiatr Scand* 80 : 250-259
- Okuma T, Yamashita I, Takahashi R, Itoh H, Otsuki S, Watanabe S, Sarai K, Hazama H, Inanaga K(1989)** : Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. *Pharmacopsychiatry* 22 : 47-53
- Oyewumi LK, Vollick D, Merskey H, Plumb C(1994)** : Famotidine as an adjunct treatment of resistant schizophrenia. *J Psychiatry Neurosci* 19 : 145-150
- Pato CN, Wolkowitz OM, Rapaport M, Schulz SC, Pickar D(1989)** : Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia. *Psychopharmacol Bull* 25 : 263-266
- Plasky P(1991)** : Antidepressant usage in schizophrenia. *Schizophr Bull* 17 : 649-657
- Rahman R(1968)** : A review of treatment of 176 schizophrenic patients in the mental hospital, Pabna. *Br J Psychiatry* 114 : 775-777
- Rapaport MH, Wolkowitz OM, Kelsoe JR, Pato C, Konicki P, Pickar D(1993)** : Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients. *Neuropsychopharmacology* 9 : 111-115
- Roberts K, Vass N(1986)** : Schneiderian first rank symptoms caused by benzodiazepine withdrawal. *Br J Psychiatry* 148 : 593-594
- Salzman C(1988)** : Use of benzodiazepines to control disruptive behavior in inpatients. *J Clin Psychiatry* 49 : 13-15
- Schulz SC, Kahn EM, Baker RW, Conley RR(1990)** : Lithium and carbamazepine augmentation in treatment-refractory schizophrenia. In : *The Neuroleptic Nonresponsive Patients : Characterization and Treatment* eds by Angrist and Schulz, Washington DC, American Psychiatric Press. pp109-136
- Sheppard GP(1979)** : High dose propranolol in schizophrenia. *Br J Psychiatry* 134 : 470-476
- Silver H, Kushnir M, Kaplan A(1996)** : Fluvoxamine augmentation in clozapine-resistant schizophrenia : An open pilot study. *Biol Psychiatry* 40 : 671-674
- Siris SG(1991)** : Diagnosis of secondary depression in schizophrenia : Implication for DSM-IV. *Schizophr Bull* 17 : 75-98
- Siris SG, Bermanzohn PC, Mason SE, Schuwall MA(1994)** : Maintenance imipramine for secondary depression in schizophrenia : A controlled trial. *Arch Gen Psychiatry* 51 : 109-115
- Siris SG, van Kammen DP, Docherty JP(1978)** : The use of antidepressant medication in schizophrenia. a review of the literature. *Arch Gen Psychiatry* 35 : 1368-1377
- Spina E, DeDomenico P, Ruelo C, Longobardo N, Gitto C, Ancione M, DiRosa AE, Caputi AP(1994)** : Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients. *Int Clin Psychopharmacol* 9 : 281-285
- Tendon R, Greden JF, Silk KR(1988)** : Treatment of negative schizophrenic symptoms with trihexyphenidyl. *J Clin Psychopharmacol* 8 : 212-215
- Terao T, Oga T, Nozaki S, Ohta A, Otsubo Y, Yamamoto S, Zam-**

- ami M, Okada M(1995)** : Lithium addition to neuroleptic treatment in chronic schizophrenia : A randomized, double-blind, placebo controlled, cross-over study. *Acta Psychiatr Scand* 92 : 220-224
- Weiner RD(1979)** : The psychiatric use of electrically induced seizure. *Am J Psychiatry* 136 : 1507-1517
- Weiner RD, Coffey CE(1988)** : Indication for use of electroconvulsive therapy. In : Frances AJ, and Hales RE eds. *Review of psychiatry*. vol 7. Washington DC, American Psychiatric Press. pp458-481
- Wettling T(1987)** : Open clinical trial of carbamazepine in chronic schizophrenic inpatients. *Pharmacopsychiatry* 20 : 127-130
- Wilson WH(1993)** : Addition of lithium to haloperidol in affective, antipsychotic nonresponsive schizophrenia : A double blind, placebo controlled, parallel design clinical trial. *Psychopharmacology* 111 : 359-366
- Wolkowitz OM, Pickar D(1991)** : Benzodiazepine in the treatment of schizophrenia : A review and reappraisal. *Am J Psychiatry* 148 : 714-726
- Wolkowitz OM, Pickar D, Doran AR, Breier A, Tarell J, Paul SM (1986)** : Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia. *Am J Psychiatry* 143 : 85-87
- Wolkowitz OM, Turetsky N, Reus VI, Hargreaves WA(1992)** : Benzodiazepine augmentation
- Yassa R, Nastase C, Belzile L(1989)** : Lorazepam as an adjunct in the treatment of auditory hallucination in a schizophrenic patients (letter). *J Clin Psychopharmacol* 9 : 386